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Background: Previously we have examined the effect of maternal dietary n-3 long-chain polyunsaturated fatty acid
(LCPUFA) supplementation during pregnancy on offspring fat mass. Considering the involvement of the placenta in
fetal programming, we aimed to analyze the sex-specific gene expression in human term placenta and its response
to the n-3 LCPUFA intervention, as well as their correlations to offspring adiposity.
Results: Placental gene expression was assessed in a control and n-3 LCPUFA intervention group by DNA microarrays,
biological pathway analyses and RT-qPCR validation. Expression data were correlated with sex steroid hormone levels in
placenta and cord plasma, and offspring anthropometric data. Transcriptome data revealed sexually dimorphic gene
expression in control placentas per se, whereas in intervention placentas sex-specific expression changed, and more n-3
LCPUFA-regulated genes were found in female than male placentas. Sexually dimorphic gene expression and n-3 LCPUFA-
responsive genes were enriched in the pathway for cell cycle and its associated modulator pathways. Significant mRNA
expression changes for CDK6, PCNA, and TGFB1 were confirmed by RT-qPCR. CDK6 and PCNA mRNA levels correlated with
offspring birth weight and birth weight percentiles. Significantly reduced placental estradiol-17β/testosterone ratio upon
intervention found in female offspring correlated with mRNA levels for the 'Wnt signaling' genes DVL1 and LRP6.
Conclusions: Overall, human placentas show sexually dimorphic gene expression and responsiveness to maternal n-3
LCPUFA intervention during pregnancy with more pronounced effects in female placentas. The absence of correlations of
analyzed placental gene expression with offspring adipose tissue growth in the first year is not mutually exclusive with
programming effects, which may manifest later in life, or in other physiological processes.
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The concept of ‘developmental origins of health and dis-
ease’ (DOHaD) hypothesizes that intrauterine nutritional
imbalances cause an early adverse growth and can trigger
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unless otherwise stated.disease in later life, such as obesity, metabolic, and cardio-
vascular disease [1]. The prevalence of obesity in US chil-
dren and adolescents was 16.9% in 2009–2010 [2], and a
German survey showed only slightly lower rates [3]. As a
strategy for primary obesity prevention, Ailhaud and
Guesnet proposed to reduce the n-6/n-3 fatty acid ratio of
the maternal diet during pregnancy [4]. This was based on
their observation that offspring of mice fed a high-fat diet
with low n-6/n-3 fatty acid ratio before mating and during
the pregnancy/lactation period had lower body weight from
weaning until adulthood compared to offspring of mice fed
a high-fat diet with a high n-6/n-3 fatty acid ratio [4,5].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(LCPUFA) arachidonic acid it was shown to stimulate adi-
pocyte differentiation and maturation, whereas n-3 LCPU-
FAs eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) were counteractive [5]. As a proof-of-concept, we
previously performed a randomized, controlled human
intervention trial, the INFAT (Impact of Nutritional Fatty
Acids during Pregnancy and Lactation on Early Human
Adipose Tissue Development) study, and addressed as
primary endpoint whether a reduced n-6/n-3 LCPUFA
ratio in maternal nutrition during pregnancy and lactation
might represent a strategy to reduce offspring adipose
tissue growth [6]. In the INFAT study also placentas from
offspring were collected for further research exploring the
impact of the n-3 LCPUFA intervention on placental gene
expression, as described in the present work.
The placenta is suggested to play a key role in mediating
fetal metabolic programming of the offspring in utero,
because as central interface between mother and fetus the
placenta senses and adapts to environmental stimuli, espe-
cially nutritional stimuli, with alterations in nutrient trans-
port and hormone production (reviewed in [7,8]). For
human and mouse models, it has been reported that male
and female fetuses differentially respond to in utero en-
vironmental stimuli [9,10]. With regard to adipose tissue
growth and distribution, differences between male and
female are already apparent at birth [11]. Sex-specific dif-
ferences have also been described for the metabolism and
status of LCPUFAs in human subjects [12]. For instance,
higher n-3 LCPUFA tissue concentrations, especially for
DHA, were found in female than in male adults associated
with a higher synthesis rate of n-3 LCPUFAs from their
precursor alpha-linolenic acid in females. Furthermore,
Ryan et al. [13] found that DHA-supplementation of
formula in pre-term children sex-specifically decreased
the gain of body weight, body length, and head circum-
ference. In addition, they observed a lower fat-free mass in
6 months old boys, but not in 6 months old girls.
LCPUFAs and their derivatives can exert their
biological effects by modulating signal transduction via
membrane receptors or membrane composition, or serv-
ing as ligands of transcription factors, such as PPARα-γ
[14]. For human placenta, Sood et al. reported gene ex-
pression differences between human male and female pla-
centas [15]. The placenta tissue carrying the fetal genome
and sex appears as promising candidate to be involved in
mediating sex-specific functions and programming effects
on the fetus with sustainable impact [9,10,16]. In general,
the underlying mechanisms of sexually dimorphic gene
expression are not well understood. It has been shown
that genes located on sex chromosomes contribute to dif-
ferential gene expression between male and female som-
atic tissues, and sex steroid hormones are thought to
provide the initiation of sexual differentiation [10,17-19].Considering the sex-specific differences in the metab-
olism and status of LCPUFAs in human subjects, the
roles of n-6 and n-3 LCPUFAs in the regulation of gene
expression and fetal and postnatal development, and that
maternal-derived n-6 and n-3 LCPUFAs are transported
via the placenta to the fetus [20,21], we aimed in the
present study to explore whether the placental tran-
scriptomes between female and male offspring are dif-
ferent per se, and if maternal n-3 LCPUFA intervention
during pregnancy has a sex-specific impact on the pla-
cental transcriptome. Furthermore, we investigated if
observed diffential gene expression is related to sex
steroid hormone levels in placenta and umbilical cord
blood plasma, and may have a programming effect on
offspring body composition. To answer these questions,
we analyzed the gene expression in the placentas of off-
spring from defined control (Con) and n-3 LCPUFA
intervention (N3) subpopulations of the INFAT study
by transcriptome and pathway analyses, followed by
quantitative real-time polymerase chain reaction (RT-
qPCR) validation. We measured placental and umbilical
cord plasma sex steroid hormone levels, and analyzed the
gene and protein expression for aromatase (CYP19A1).
Correlation analyses were performed between the mRNA
levels of specific sexually dimorphic expressed genes and
sex steroid hormone levels, as well as offspring anthropo-
metric data. To evaluate the relation between placental
sexually dimorphic gene expression and sex steroid
hormone levels on genomic level, the DNA sequences
of identified regulated target genes were searched for
putative hormone-responsive elements of the respective
hormone receptors.
Methods
Ethics statement and subpopulations of the INFAT study
The present study on human placental gene expression
is a substudy of our previously published randomized,
controlled human intervention trial, the INFAT (Impact
of Nutritional Fatty Acids during Pregnancy and Lacta-
tion on early Human Adipose Tissue Development) study
[6]. The data of the INFAT study addressed as primary
endpoint whether a reduced n-6/n-3 LCPUFA ratio in
maternal nutrition during pregnancy and lactation might
represent a strategy to reduce offspring adipose tissue
growth [6]. The study protocol was in accordance with the
rules of the International Conference on Harmonization
Good Clinical Practice guidelines (valid from 17 January
1997), the last revision of the declaration of Helsinki
(October 2000; Edinburgh, United Kingdom) and appli-
cable to local regulatory requirements and laws. The study
protocol was approved by the ethical committee of the
Technische Universität München (1479/06/2006/2/21)
and registered at clinicaltrials.gov as NCT00362089. The
INFAT study was an open-label, monocenter, prospective,
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arm parallel group design, as described in detail by Hauner
et al. [22]. All participants gave written consent prior to
their inclusion in the study. All human materials, includ-
ing term placentas and cord blood plasma, were obtained
from participants of the INFAT study by written informed
consent according to the consent regulation [6,22].
In brief, in the INFAT study 208 women of Western
European descent with a BMI between 18 and 30 with-
out high-risk pregnancies or prior n-3 fatty acid supple-
mentation were included before the 15th week of gestation
and randomly assigned to a control (Con) or n-3 LCPUFA
intervention group (N3). Both groups were advised for a
healthy diet during pregnancy. The women of the interven-
tion group were additionally advised to decrease their diet-
ary n-6/n-3 LCPUFA ratio to about 3:1 by a daily n-3
LCPUFA supplementation (1,020 mg DHA and 180 mg
EPA) and reduction of arachidonic acid intake to 50–90
mg per day. Healthy term-born offspring (between 37th
and 42nd week of gestation) were included for further ana-
lyses. Mode of delivery, sex of the newborn, birth weight
and length, gestational age, and birth weight percentiles
were recorded from maternal obstetric records. Anthropo-
metric measurements (weight, skin folds) and abdominal
ultrasonography were conducted at 3–5 days, 6 weeks and
one year post partum, and birth weight / birth length ratio,
birth weight / placental weight ratio, sum of four skin-fold
thicknesses and subcutaneous / preperitoneal fat ratio were
calculated as reported previously [6]. Excellent compliance
was already demonstrated for the entire INFAT study
population (n = 208), including also all women of the
present INFAT substudy. Moreover, this compliance was
also reflected by LCPUFA biomarker for maternal red
blood cells (RBC) and offspring cord RBC of the subpopu-
lations, comprising INFAT participants and their offspring
from the control (Con) and n-3 LC-PUFA intervention
(N3) group and used in the present study for transcriptome
analysis (n = 16) and validation experiments (n = 41) as
shown in Additional file 1: Table S1 and S2. The data for
the individual subjects are derived from already published
data of the whole INFAT subpopulation [6,23].
The selection of the analyzed INFAT study subpopula-
tions for this study was determined by minimizing the
influences of birth mode and consideration of the use of
analgesics or anesthetics on placental gene expression
[24-27]. Therefore, all analyzed placentas were derived
from offspring of mothers with healthy pregnancies ex-
cluding mothers and offspring with pregnancy complica-
tions. These offspring were born by vaginal delivery and
considered as appropriate for gestational age (10th - 90th
percentile of birth weight). For subsequent analyses, data
from study participants and their offspring, including
placenta, were divided in control group (Con, n = 20)
and n-3 LCPUFA intervention group (N3, n = 21). Toidentify sex-specific effects, data were stratified for
offspring sex resulting in additional six groups: group 1:
female offspring of Con (Con-F, n = 11); group 2: male
offspring of Con (Con-M, n = 9); group 3: female off-
spring of N3 (N3-F, n = 10); group 4: male offspring of
N3 (N3-M, n = 11), group 5: female offspring of Con
and N3 together (Con/N3-F, n = 21); group 6: male
offspring of Con and N3 together (Con/N3-M, n = 20).
The main clinical characteristics of subpopulation
mothers and offspring are presented in Additional file 1:
Table S2.
Placenta and cord blood sampling
Having obtained written informed consent, placenta was
weighed and placental samples were dissected from each
of the four quadrants with the same distance to the pla-
centa center according to a standardized sampling protocol.
Regions with large vessels or calcifications were avoided for
sampling. To obtain the chorionic villous portion of the
placenta, the maternal basal and fetal chorionic plate of
each placenta sample were removed. Placenta samples were
immediately snap-frozen. Cord blood was collected into
EDTA tubes and centrifuged at 4°C with 2,000 g for 10
min. Cord plasma and placenta samples were stored
at −80°C until further processing.
Extraction of total RNA
For each placenta, tissue samples from the four quad-
rants were homogenized in TRIzol® Reagent (Invitrogen,
Darmstadt, Germany) and pooled in equal parts for total
RNA extraction by midi RNeasy Kit (Qiagen, Hilden,
Germany). Total RNA was quantified with NanoDrop™
1000 Spectrophotometer (Peqlab, Erlangen, Germany).
RNA integrity number (RIN) was analyzed by the Bioana-
lyzer 2100 (Agilent Technologies, Böblingen, Germany).
DNA microarray analysis
For transcriptome analysis, the influences of birth mode
and the use of analgesics or anesthetics on placental gene
expression [24-27] were minimized by using only placen-
tas from offspring that were obtained by vaginal delivery,
were appropriate for gestational age newborns (10th - 90th
percentile of birth weight), and where no cervical ripening
agents (mostly n-6 LCPUFA derivatives), analgesics or an-
aesthetics were administered during labor of healthy preg-
nancies. Hence, experiments and data analyses were
performed using female (Con-F, n = 4) and male (Con-M,
n = 3) placentas from the control group, and female (N3-F,
n = 4) and male (N3-M, n = 5) placentas from the n-3
LCPUFA intervention group. The main clinical character-
istics of mothers and offspring of the subpopulation for
DNA microarray analysis are presented in Additional file
1: Table S1.
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bridized to Affymetrix Custom Array - NuGO_Hs1a520180
array, containing 17699 genes [28]. All steps and controls
of DNA microarray processing were performed according
to the manufacturer’s protocol (Affymetrix Inc., Santa
Clara, CA, USA). RNA from each individual placenta
was applied to individual DNA microarrays which were
then processed altogether. MADMAX (Management and
Analysis Database for Multi-platform microArray eXperi-
ments) was used for quality control, normalization [gc Ro-
bust Multichip Average (slow)], annotation by custom
CDF-file 13.0.0, and statistical analysis [29]. For Principal
Component Analysis (PCA), normalized MADMAX DNA
microarray data were used and analyzed with the
"prcomp" function of the R statistical software. In MAD-
MAX, fold changes and P-values were calculated in mod-
erated t-tests using the R Bioconductor LIMMA package.
For the identification of significantly regulated genes in
the placenta considering the effects of n-3 LCPUFA inter-
vention and sex, DNA microarray data analyzed by MAD-
MAX program were further processed in six different
comparisons as described in detail in the Results section.
Fold changes (FC) of ≤ −1.5 and ≥ +1.5 (P < 0.05) were
considered as significantly differential gene expression.
DNA microarray data have been curated, accepted and
deposited in NCBI’s Gene Expression Omnibus [30]




The metabolic pathways from wikipathways_Homo_sapi-
ens_Curation-AnalysisCollection_gpml (downloaded 2010-
11-04) and Hsa-KEGG_20100914 were combined and
loaded into PathVisio 3.1.3, together with the gene database
Hs_derby_20100601.bridge [31]. Positive Z-scores > 0 indi-
cated pathways which contain significantly regulated genes
from the DNA microarray data sets in an overrepresenta-
tive manner [32].
To indicate the mean direction of gene expression
changes for all genes expressed in the respective path-
ways, the mean centroid value analyses were performed.
For this analysis, all log2 intensity data measured by
DNA microarray for the genes assigned to the pathway
were normalized to a mean of zero and a variance of
one per gene across all placentas of the respective com-
parison (e.g. only control placentas were used for the
comparison Con-M vs. Con-F). A mean centroid value
for each placenta over all genes per pathway was calcu-
lated [33]. From this mean centroid value per placenta a
further mean for each analysis group (Con-M, Con-F,
Con-M + F, N3-M, N3-F, N3-M + F) in the five compari-
sons was used to indicate the mean direction of gene ex-
pression changes for the pathways.Gene expression analysis
RT-qPCR was conducted with 10 ng of total RNA and the
QuantiTect SYBR Green RT-PCR Kit (Qiagen, Hilden,
Germany) in combination with self-designed intron-
spanning primer pairs or validated quantitect primer as-
says (Qiagen, Hilden, Germany; see Additional file 1: Table
S3). The mean RIN of the analyzed RNAs was 6.8 ± 0.4
(SD). The cycling conditions were: 1 cycle at 50°C for 30
min, 1 cycle at 95°C for 15 min, 40 cycles at 95°C for 15
sec/60°C (or as stated in Additional file 1: Table S3) for 30
sec/72°C for 30 sec, and a terminal melting curve. Reac-
tions were controlled by ‘no RT’ and ‘no template’ con-
trols. Melt curve analysis showed, that all RT-qPCR
reactions for the analyzed samples in each primer pair
were free of primer dimers. Efficiency of primer pairs was
assessed by LinRegPCR [34]. Efficiency of used primer
pairs was 1.866 ± 0.037 (SD) and therefore, no efficiency
correction was applied for calculation of relative gene
expression levels. Relative gene expression levels were
calculated by the 2^(−ΔΔCt) method [35], including
normalization to ACTB, B2M, POLR2A, and TOP1 as
reference genes which were selected from literature for
their application as reference genes in placenta tissue
[36,37]. In our study, the suitability of these reference
genes was confirmed, since no significant differences
between the analyzed groups were observed after ana-
lyzing the Cq mean for all four genes together and by
bestkeeper [38].
Sex steroid hormone analysis in placental tissue and cord
plasma
Concentrations of the sex steroid hormones progesterone,
testosterone (T), estradiol-17β (E2) and total estrogen in
cord plasma and placenta samples were determined using
enzyme immunoassays according to Prakash et al. [39],
Blottner et al. [40] and Meyer et al. [41], respectively. For
the progesterone ELISA, a primary antibody directed
against progesterone-7α-carboxyethylthioether (kindly
donated by Frank Weber, Clinic for Ruminants, Ludwig-
Maximilians Universität München, Germany) was used.
Plasma aliquots from cord blood (50 μl) were extracted
with 30% tertiary butylmethylether/70% petroleum ether
(v/v). After freezing at −60°C over night, the supernatants
were decanted, dried, diluted in assay buffer, and subjected
to the respective ELISA. To determine the total amount of
conjugated estradiol-17β and total estrogen, the water resi-
due after extraction was hydrolyzed with β-glucuronidase /
arylsulfatase (from Helix pomatia; Merck, Grafing,
Germany) at 37°C for 2 h according to Meyer et al. [42]
and subjected to a second alcohol extraction. The hormone
concentration of placental tissue was determined following
Blottner et al. [40]. The lower detection limit for T, proges-
terone, E2, and total estrogens was 0.05 ng/mL, 0.5 ng/mL,
20.0 pg/mL and 20.0 pg/mL in plasma, and 0.025 ng/g, 2.5
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plasma intra- and interassay coefficient of variations were <
10%.
Western blot analysis
Equal amounts of placental protein extracts (60 μg pro-
tein per lane) were denatured and then separated by a
10% SDS-PAGE. Subsequently, proteins were transferred
to a nitrocellulose membrane using semi-dry blotting
(Biometra, Göttingen, Germany). For antigen detection,
membranes were incubated with primary antibodies goat
anti-human aromatase CYP19A1 [#8799 (1:1,000), Cell
Signaling, Frankfurt am Main, Germany], and mouse
anti-GAPDH [AM4300 (1:10,000), Ambion Inc./Life
Technologies, Darmstadt, Germany] over night at 4°C.
GAPDH protein expression was used as invariant con-
trol. For the detection of primary antibodies, membranes
were incubated with donkey anti-goat antibody conjugated
with IRDye 800CW and donkey anti-mouse antibody con-
jugated with IRDye 680RD (1:10,000 each; LI-COR Biosci-
ences GmbH, Bad Homburg, Germany) for one hour at
room temperature. For signal detection and densitometric
analysis, the Odyssey Infrared Detection and Imaging
System and the Odyssey application software v3.0 (LI-COR
Biotechnology, Bad Homburg, Germany) were used,
respectively.
Assessment of putative hormone-responsive transcription
factor binding elements
The UCSC Genome Browser on Human Mar. 2006 (NC
BI36/hg18) Assembly of the Encyclopedia of DNA ele-
ments (ENCODE) consortium (http://genome.ucsc.edu/)
was used for the analysis of putative hormone-responsive
elements of the androgen receptor and the estrogen re-
ceptors alpha and beta [43]. The validated genes were in-
vestigated for HMR (human, mouse, rat) conserved
transcription factor binding sites within the nearest neigh-
boring gene upstream to the nearest neighboring gene
down-stream of the respective strand.
Statistical analysis
For statistical analysis, a two-way ANOVA approach was
used to assess the factors n-3 LCPUFA intervention
[(N3-M + F, n = 21) vs. (Con-M + F, n = 20)], offspring
sex [(Con/N3-M, n = 20) vs. (Con/N3-F, n = 21)], and
their interactions. With the post-hoc test Holm-Sidak pair-
wise comparisons of the intervention and control group
stratified for sex were conducted: group 1: placentas of
female offspring in the control group (Con-F, n = 11);
group 2: placentas of male offspring in the control group
(Con-M, n = 9); group 3: placentas from female offspring
in the n-3 LCPUFA intervention group (N3-F, n = 10);
group 4: and placentas from male offspring in the n-3
LCPUFA intervention group (N3-M, n = 11). Normallydistributed variables, as assessed by Shapiro-Wilk test,
were analyzed by two-way ANOVA. Sex steroid hormone
data and other not normally distributed variables, or vari-
ables that violated homoscedascity, were analogously ana-
lyzed by a two-way ANOVA on ranks. Significant results
of two-way ANOVA and two-way ANOVA on ranks were
further analyzed by pairwise comparison with Holm-Sidak
post-hoc test. Two-sided P-values < 0.05 were considered
as significant. All tests were carried out with Sigma Plot
11.0 (Systat Software GmbH, Erkrath Germany). For bi-
variate correlation analysis, non-parametric Spearman-rho
correlation coefficient (Rs) and two-sided significance were
calculated with IBM SPSS Statistics 19 (IBM Deutschland
GmbH, Ehningen, Germany). P-values < 0.05 were consid-
ered as significant correlations, and correlation coefficients
between 0.0 - 0.4, 0.4 - 0.7, and 0.7 - 1.0 were considered
as weak, moderate, and strong correlations, respectively.
Results
Maternal and offspring clinical characteristics of the
INFAT subpopulations
To ensure that the main clinical characteristics of INFAT
study subpopulation mothers and their offspring, and the
compliance of the n-3 LCPUFA intervention are represen-
tative for the respective data of the whole INFAT study
[6,23], we analyzed the subpopulations according their
usage in the DNA microarray approach and validation
experiments stratified for sex (Additional file 1: Table S1
and S2). The analyses of clinical characteristics and
LCPUFA biomarker of maternal RBC at week-15 of preg-
nancy (baseline) showed no significant differences. How-
ever, for pregnant mothers at week-32 of pregnancy and
offspring cord RBC significantly lower n-6/n-3 LCPUFA
ratio in the n-3 LCPUFA intervention compared to the
control group were observed, as already reported for the
whole INFAT study [6,23]. These data of the subpopula-
tions in the present study reflect the published excellent
compliance of the INFAT study and clearly demonstrate
that the n-3 LCPUFA intervention reduces the n-6/n-3
LCPUFA ratio as expected. This confirms that pregnant
women with a normal dietary record are not in a state of
dietary n-3 LCPUFA saturation, since they respond to the
n-3 LCPUFA intervention as shown by increased levels of
n-3 LCPUFA in maternal RBC and offspring cord RBC
compared to the control group [22,44].
Placentas show sexually differential gene expression per se
A DNA microarray approach was applied to 16 placentas
from male and female offspring of the INFAT study sub-
population to evaluate sexually differential gene expres-
sion per se and its responsiveness to maternal dietary n-3
LCPUFA intervention during pregnancy. First, the extent
of the effects intervention and sex was assessed in an
unsupervised approach for all genes by a principal
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data (Figure 1A). For the data of the first 3 components
highlighting intervention and offspring sex as shown in
the plots of PC1 vs. PC2 and PC2 vs. PC3 (Figure 1A), the
data points neither for intervention nor for offspring sex
were clearly aligned with one of these principal compo-
nents. This result was not surprising, since placental geneFigure 1 Principal component analysis (PCA) and Venn diagrams of s
expression data from DNA microarrays. Each circle represents one analyzed
(PC): empty circles, control group (Con); filled circles, n-3 LCPUFA intervent
Lines connect outer values of the respective placenta groups: green stipple
female placentas of N3 and Con, respectively; blue and stippled blue, male
female and male placentas is represented by red and blue areas, respective
compare the number and intersections of significantly regulated transcripts
the various data sets. (B) Green and amber colored Venn diagrams represe
female placentas in Con [(Con-M; n = 3) vs. (Con-F; n = 4)] and N3 [(N3-M;
diagrams show the number of significantly regulated transcripts between N
placentas [(N3-F; n = 4) vs. (Con-F; n =4)], respectively, and for male and fe
n = 9) vs. (Con-M + F; n = 7)]. White symbols, Con; black symbols, N3; Con
female placentas from N3; N3-M, male placentas from N3; arrows up or doexpression is a highly complex system with a large number
of regulating factors which may also depend on variable
maternal parameters. Accordingly, it cannot be expected to
find offspring sex to be dominant enough to result in a
strong separation in an analysis taking into account all
genes present on the DNA microarray. However, visual in-
spection and highlighting the lines connecting the outerignificantly regulated placental transcripts. (A) PCA of gene
placenta (n = 16) projected on the first three principal components
ion group (N3); red circles, female offspring; blue circles, male offspring.
d, control placentas; amber, all N3 placentas; red and stippled red,
placentas of N3 and Con, respectively. Variability of data points for all
ly, enclosing corresponding outer values. (B,C) Shown Venn diagrams
(+1.5 ≤ FC ≤ −1.5, P < 0.05) identified by DNA microarray analysis for
nt the number of significantly regulated transcripts between male and
n = 5) vs. (N3-F; n = 5)], respectively. (C) Red and blue colored Venn
3 and Con for male [(N3-M; n = 5) vs. (Con-M; n = 3)] and female
male placentas together and adjusted for offspring sex [(N3-M + F;
-F, female placentas from Con; Con-M, male placentas from Con; N3-F,
wn depict higher or lower expression related to the respective group.
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between all placentas of the control and intervention
group, and (ii) subdivide further these groups by sex, point
to a sex-specific effect within the group per se and upon
the n-3 LCPUFA intervention (Figure 1A).
Next, DNA microarray data were analyzed to identifiy
significantly regulated genes considering the effects of n-3
LCPUFA intervention and sex using the following six dif-
ferent comparisons and the MADMAX program. For off-
spring sex, male placentas were compared to female
placentas separately in the (i) control group [(Con-M, n =
3) vs. (Con-F, n = 4)] and (ii) intervention group [(N3-M, n
= 5) vs. (N3-F, n = 4)]. To analyze the effect of n-3 LCPUFA
intervention, pooled data from male and female placentas
of the intervention group were compared to pooled data
from male and female placentas of the control group (iii)
without adjusting for offspring sex [(N3, n = 9) vs. (Con, n
= 7)] and (iv) with adjusting for offspring sex [(N3-M+ F, n
= 9) vs. (Con-M+ F, n = 7)] by using a model including a
sex term. Moreover, to identify sex-specific effects of the
intervention, the DNA microarray data were stratified for
offspring sex. The factor intervention was analyzed (v) in
female [(N3-F, n = 4) vs. (Con-F, n = 4)] and (vi) male
placentas [(N3-M, n = 5) vs. (Con-M, n = 3)]. Gene
expression fold changes (FC) of ≤ −1.5 and ≥ +1.5 (P < 0.05)
were considered as statistically significant. The main results
of these analyses are described as follows and illustrated by
Venn diagrams in Figure 1B and C.
We first assessed whether placental gene expression
differences exist per se between the sexes independent of
the n-3 LCPUFA intervention by analyzing the data set
(Con-M vs. Con-F) of the control group (Figure 1B). 399
significantly differentially expressed genes were identified.
216 (54.1%) genes showed higher expression in female
placentas, whereas 183 (45.9%) genes were higher expressed
in male placentas. In the data set (N3-M vs. N3-F) of the
intervention group, only 65 differentially expressed genes
were found (Figure 1B), and more genes were significantly
higher expressed in male [41 (63.1%)] than female placentas
[24 (36.9%)]. Furthermore, 12 genes were only in common
for both groups as depicted in the Venn diagram inter-
section area. The remaining 387 (control) and 53 (inter-
vention) genes showed sexually dimorphic expression in a
group-restricted manner. For chromosomal localization of
the genes in the intersection area, the genes for DDX3Y,
EIF1AY, KDM5D, RPS4Y1, USP9Y, UTY, and ZFY are lo-
cated on Y-chromosome, the genes for HDHD1A, KDM6A,
and ZNF711 are on X-chromosome, and the genes LIMCH1
and SSB are located on autosomes. The genes DDX3Y,
EIF1AY, KDM5D, RPS4Y1, USP9Y, UTY, ZFY, and ZNF71
showed significantly higher expression in male than female
placentas, whereas the genes HDHD1A, KDM6A, and SSB
were significantly higher expressed in female than male pla-
centas in both the control group and the interventiongroup. For LIMCH1, an opposing gene expression between
the groups was observed (Additional file 1: Table S4
provides expression fold changes of some of these genes
and their relation to placental transcriptome studies by Sood
et al. [15] and Tsai et al [37]). Interestingly, the X-
chromosome-linked genes HDHD1A and KDM6A were
nearly two-fold higher expressed in female than male
placentas confirming reports that they escape X-inactivation
in humans [45-47].
Importance of offspring sex in placental gene expression
analyses
The reason to include the term sex in our statistical ana-
lysis was based on our initially interesting observation that
in the data set (N3 vs. Con; not adjusted for offspring sex)
only 22 genes in total were significantly regulated between
the intervention and control group (10 up-regulated
genes, 12 down-regulated genes). However, after adjusting
this data set for offspring sex (N3-M+ F vs. Con-M + F),
222 significantly regulated genes upon intervention were
found (Figure 1C). Importantly, more genes were down-
regulated [161 (72.5%)] than up-regulated [61 (27.5%)]
upon intervention.
The evaluation whether the intervention impacts gene
expression differently in male and female placentas (N3-F
vs. Con-F) led to the identification of 239 n-3 LCPUFA-
regulated genes in female placentas (N3-F vs. Con-F) [80
(33.5%) up-regulated genes; 159 (66.5%) down-regulated
genes], whereas for male placentas (N3-M vs. Con-M)
only 93 genes were found [34 (36.6%) up-regulated genes;
59 (63.4%) down-regulated genes]. Most of the genes were
unique for one of the three data sets: 65 genes (N3-M vs.
Con-M), 133 genes (N3-M+ F vs. Con-M+ F), and 166
genes (N3-F vs. Con-F) as shown in Figure 1C.
For n-3 LCPUFA-regulated genes common in two data
sets, only 22 genes (N3-M + F vs. Con-M + F; N3-M vs.
Con-M), and 67 genes (N3-M + F vs. Con-M + F; N3-F
vs. Con-F) without changes of regulation direction for
both respective data sets were found. In contrast, for the
data sets (N3-M vs. Con-M) and (N3-F vs. Con-F), the only
common genes with significantly differential expression
were CKS2, C8orf59, EPS8L2, GALNT11, LIMCH1, and
STRA6, but these genes showed an inverse regulation. n-3
LCPUFA-regulated genes common to all three analyzed
data sets were not found.
Identification of n-3 LCPUFA-responsive genes and
pathways
Since there was a lack of data in the literature on placental
transcriptome analysis with regard to n-3 LCPUFA inter-
vention during pregnancy, the expression of known classical
LCPUFA-regulated genes that were already predominantly
described in non-placental tissues, such as adipose tissue
and liver [14,48,49], were evaluated by our placental
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showed minor placental expression changes in response to
n-3 LCPUFA intervention (for details see Additional file 1:
Text S1, Tables S5-S7). We therefore searched for alterna-
tive n-3 LCPUFA-responsive genes and biological pathways
by applying Pathvisio pathway analysis to our transcriptome
data sets. Table 1 shows the top ten ranked pathways as
follows, which (i) had a significantly overrepresented num-
ber of regulated genes (Z-score > 0) according to Pathvisio,
(ii) were present in at least two of the five analyzed DNA
microarray data sets, and (iii) included more than four
significantly regulated genes per pathway: ‘Cell cycle A’,
‘Insulin signaling’, ‘Oocyte meiosis’, ‘Cell cycle B’, ‘Cytokine-
cytokine receptor interaction’, ‘Adipogenesis’, ‘B cell recep-
tor signaling’, ‘Wnt signaling’, ‘TGFB receptor signaling’,
and ‘Myometrial relaxation and contraction’. In addition,
11 different genes showing each an overlap for significant
expression regulation with regard to both the sex and the
n-3 LCPUFA intervention in at least one specific pathway
were identified (Table 1).
To characterize the general direction of gene expression
changes in the pathways with regard to effects of sex and
intervention, we performed mean centroid value analyses
for the specific pathways (Figure 2). Since positive and
negative mean centroid values suggest higher and lower
gene expression in all analyzed genes in the pathway,
respectively, the following main findings for sex and inter-
vention effects, considering mean centroid values > + 0.01
and < − 0.01, were obtained. The data set (Con-M vs. Con-F)
indicated for the identified pathways ‘Cell cycle A’, ‘Oocyte
meiosis’, ‘Cell cycle B’, ‘B cell receptor signaling’, ‘Wnt signal-
ing’, ‘TGFB receptor signaling’, and ‘Myometrial relaxation
and contraction’ a down-regulation in male compared to
female placentas, whereas for the pathways ‘Adipogenesis’
and ‘Insulin signaling’ the opposite direction was observed.
For the effect of intervention on female placentas specific-
ally (N- 3-F vs. Con-F), gene expression in the pathways
‘Cell cycle A’, ‘Cell cycle B’, ‘B cell receptor signaling’,
‘Wnt signaling’, and ‘TGFB receptor signaling’ appeared
to be down-regulated compared to controls, whereas for
the pathways ‘Oocyte meiosis’ and ‘Adipogenesis’ an
up-regulated gene expression was observed. For male
placentas (N-3-M vs. Con-M), the analysis pointed to a
down-regulation of gene expression in the pathway ‘Insulin
signaling’ and an up-regulated gene expression in the path-
way ‘Myometrial relaxation and contraction’.
RT-qPCR validation of placental genes
For a gross validation by RT-qPCR of our findings on n-3
LCPUFA-responsive genes and biological pathways, RNAs
from placentas of the control (Con-F, n = 10; Con-M,
n = 11) and intervention (N3-F, n = 11; N3-M, n = 9)
group were analyzed individually. We focused on the
genes for ANAPC4, CDK1, CDK6, HDAC5, MAD2L1, andTGFB1, which were found to be significantly expressed in
the two biological pathways ‘Cell cycle A’ and ‘Cell cycle B’,
but additionally also in other presented pathways of this
study (Table 1). Furthermore, the gene for PCNA, known
as general cell proliferation marker [50], was also validated,
since it almost reached the significant FC level in our tran-
scriptome analysis (N3-F vs. Con-F; FC: +1.4; P = 0.004).
As shown in Figure 3, apart from the n-3 LCPUFA-
responsive genes, we validated the following genes present
in the respective pathways [51,52]: LPL and TGFB1 (up-
stream regulators of cell cycle), ANAPC4 (‘TGFB receptor
signaling’), and DKK1, DVL1, FZD7, LRP6, and SFRP1
(‘Wnt signaling’). For the ‘Cell cycle’ (Figure 3A), CDK6
and PCNA gene expression were significantly higher in the
intervention than control group by applying two-way
ANOVA on ranks. Applying post-hoc tests showed only
significant differences (expressed as mean ± SD in % of
Con-F) between the female placentas of the intervention
and control group [N3-F vs. Con-F: CDK6 132 ± 49% vs.
100 ± 37%, PN3-F vs. Con-F = 0.046; PCNA 134 ± 55% vs.
100 ± 17%, PN3-F vs. Con-F = 0.005]. The two-way ANOVAs
for HDAC5 and TGFB1 revealed significant interactions
between the intervention and offspring sex. The post-hoc
test for HDAC5 demonstrated significantly higher mRNA
expression in male than female placentas of the control
group [Con-M vs. Con-F: 135 ± 52% vs. 100 ± 41%, PCon-M
vs. Con-F = 0.016], but not in the intervention group. Fur-
thermore, post-hoc analysis for TGFB1 showed also a sig-
nificant difference between male and female placentas in
the control group (Con-M vs. Con-F: 160 ± 71% vs. 100 ±
46%, PCon-M vs. Con-F < 0.001), but not in the intervention
group. At the same time, TGFB1 expression in female pla-
centas was significantly higher by 32% in the intervention
than control group (N3-F vs. Con-F: 132 ± 48% vs. 100 ±
46%, PN3-F vs. Con-F = 0.018), whereas TGFB1 expression
was significantly lower by 44% in male placentas of the
intervention group compared to the control group (N3-M
vs. Con-M: 116 ± 50% vs. 160 ± 71%, PN3-M vs. Con-M =
0.016). No significant difference in expression was observed
for ANAPC4, CDK1, andMAD2L1.
For the ‘Wnt signaling’ genes DVL1 and LRP6 (Fig-
ure 3B), two-way ANOVA analyses revealed significant ex-
pression differences between the intervention and control
group, as well as significant differences between male and
female placentas, respectively [DVL1 (Con-M vs. Con-F):
122 ± 41% vs. 100 ± 41%, PCon-M vs. Con-F = 0.009; LRP6
(N3-F vs. Con-F): 84 ± 30% vs. 100 ± 33%, PN3-F vs. Con-F =
0.049]. There was no significant gene expression differ-
ence measured for DKK1, FZD7, LPL, and SFRP1.
Sex steroid hormone levels in placental tissue and cord
plasma
Since sex steroid hormones are major determinants of
sexual dimorphism [17,53], sex steroid hormone levels were




Sex n-3 LCPUFA intervention Genes overlapping for
sex & n-3 LCPUFACon-M vs. Con-F N3-M vs. N3-F N3-F vs. Con-F N3-M vs. Con-M -M + F vs. Con-M + F§
Cell cycle A Z: 1.2; GSK3B, CDKN1A, YWHAB, CCNH, CDK6 - Z: 3.1; TGFB1, SMC3, MAD2L1,
ANAPC4, CDK6, CDK1




Insulin signaling Z: 2.9; SH2B2, TRIP10, GSK3B, FASN, CALM1,
PRKX
- Z: 2.1; PRKACB, SH2B2, RHOQ,
PPP1R3D, PYGL




Oocyte meiosis† Z: 2.4; PRKX, PPP3CA, CALM1, CAMK2G,
YWHAB
- Z: 3.3; PRKACB, CDK1, ANAPC4,
SMC3, MAD2L1, PPP3CA




Cell cycle B Z: 1.1; GSK3B, CDK6, CDKN1A, CCNH - Z:3.2; TGFB1, CDK6, CDK1,
MAD2L1, HDAC5






- Z: 2.6; CXCR7,
CCR5, LEP, BMP2
Z: 0.7; IL8, FLT4, TGFB1, CSF3R
CCL13,




Adipogenesis† Z: 4.5; LIFR, IL6ST, DVL1, FRZB, ID3, SREBF1,
MBNL1, NRIP1, CDKN1A, LPL, LPIN1






Z: 1.5; RAP2A, PIK3AP1, SH2B2, ATP2B4,
GSK3B, ACTR2, RASGRP3, CDK6, PPP3CA
- Z:2.4; PIK3AP1, SH2B2, PP3CA,
CDK6, HDAC5, BCL6
- PIK3AP1, SH2B2, PP3CA,
CDK6
144/159
Wnt signaling Z: 2.5; SFRP1, GSK3B, PRKX, TBL1X, ROCK1,
CAMK2G, PPP3CA, DVL1, FZD6
- Z: 1.8; SFRP1, LRP6, PRKACB,
TBL1X, PPP3CA




Z: 1.1; ROCK1, DVL1, CAMK2G, CDKN1A,
CDK6, YAP1






Z: 2.4; GNB1, GUCY1A3, ACTB, CALM1, RGS5,
YWHAB, CAMK2G
- - Z: 4.1; IGFBP1, PRKAR1B,
CXCR7, RXFP1, GNG8
146/161
M, number of genes measured by DNA microarray and annotated in the pathway; TP, total number of genes annotated in the pathway; §adjusted for offspring sex; Z score = (significantly regulated genes – expected
genes)/(standard deviation of significantly regulated genes); −, pathways without positive Z-scores, or if less than four genes are significantly regulated in the pathwa pathway includes significantly overrepresented
differentially expressed genes that are also present in the pathways ‘Cell cycle A’ and ‘Cell cycle B’. Pathways and genes selected for biological validation are marked old. Con-M, placentas of male offspring in the control






















































M / TP Con-M CON-F N3-M N3-F N3-F Con-F N3-M Con-M N3-M+F Con-M+F
Cell cycle A
114 / 131 - 0.071 + 0.054 - 0.064 + 0.064 + 0.034 - 0.027
Insulin signaling
126 / 147 + 0.014 - 0.011 - 0.011 + 0.018
Oocyte meiosis
103 / 122 - 0.069 + 0.052 + 0.045 - 0.045 - 0.016 + 0.021
Cell cycle B
81 / 94 - 0.063 + 0.047 - 0.057 + 0.057 - 0.025 + 0.032
Cytokine-cytokine receptor
interaction      228 / 267 - 0.016 + 0.021
Adipogenesis
118 / 131 + 0.039 - 0.029 + 0.026 - 0.026
B cell receptor signaling
144 / 159 - 0.050 + 0.038 - 0.016 + 0.016
Wnt signaling
139 / 162 - 0.053 + 0.040 - 0.028 + 0.028
TGFB receptor
signaling 134 / 152 - 0.024 + 0.018 - 0.030 + 0.030
Myometrial relaxation
and contraction 146 / 161
- 0.044 + 0.033 + 0.013 - 0.021
Figure 2 Difference of mean centroids between the analysis groups indicating the direction of gene expression changes in the
pathways. Mean centroid values of the analyzed groups are shown for the different data sets. Positive and negative mean centroid values
represent up-regulation (red) and down-regulation (green) of gene expression, respectively. M, number of genes measured by DNA microarray
and annotated in the pathway; TP, total number of genes annotated in the pathway; §, adjusted for offspring sex; Con-M, placentas of male
offspring in the control group; Con-F, placentas of female offspring in the control group; N3-M, placentas of male offspring in the n-3 LCPUFA
intervention group; N3-F, placentas of female offspring in the n-3 LCPUFA intervention group.
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cental gene expression in our study. Free and conjugated
E2, free and conjugated total estrogen, T, progesterone, and
the E2/T ratio in placental tissue (n = 41) and cord plasma
(n = 34) were measured. For T, a significant effect of off-
spring sex in cord plasma and placenta was detected by
two-way ANOVA analysis on ranks (Figure 4A and C),
whereas no significant effects were observed for the other
analyzed sex steroid hormones progesterone and estrogens
in cord plasma or placenta considering intervention or off-
spring sex (see Additional file 1: Table S8). Post-hoc analysis
for cord plasma T (Figure 4A) detected a significantly lower
T level by 12.5% in female than male placentas independent
of intervention [Con-M: 1.3 (1.0 - 1.3) ng/ml; Con-F: 1.1
(0.8 - 1.3) ng/ml; N3-M: 1.2 (1.0 - 1.4) ng/ml; N3-F: 0.9
(0.8 - 1.1) ng/ml; (Con/N3-M) vs. (Con/N3-F); P# =
0.049]. However, post-hoc analysis for placental T revealed
significantly higher levels by 54.3% in female compared to
male placentas from the intervention group [median
(IQR): 19.7 (16.6 - 22.6) ng/g N3-F placenta vs. 10.7 (9.7 -
14.4) ng/g N3-M placenta; PN3-M vs. N3-F = 0.008], but no
significant differences in control placentas as shown in
Figure 4C. To further analyze the differences in hormone
levels between the groups, the E2/T ratio was calculated
and used as activity index for aromatase (CYP19A1) which
executes the transformation of T to E2 [54]. Interestingly,
significant effects of offspring sex and interaction of
sex with the intervention were observed for the placental
E2/T ratio using two-way ANOVA on the ranks(Figure 4D). Post-hoc analysis showed a significantly
higher E2/T ratio by 171.4% in male than female placentas
upon n-3 LCPUFA treatment [5.7 (3.6 - 6.3) ng/g N3-M
vs. 2.1 (1.7 - 3.7) ng/g N3; PN3-M vs. N3-F = 0.002], but not
in the control. Additionally, post-hoc analysis revealed a
significantly lower E2/T ratio by 49.9% for female placentas
of the intervention than control group [2.1 (1.7-3.7) ng/g
N3-F vs. 4.2 (2.5-6.1) ng/g Con-F; PN3-F vs. Con-F = 0.042]
reflecting significantly higher T levels in N3-F compared to
Con-F placentas without significant difference for E2. For
male placentas (N3-M vs. Con-M), however, no significantly
different E2/T ratio was found. Moreover, cord plasma E2/
T ratios between the analyzed groups were also not signifi-
cantly different (Figure 4B).
Placental gene and protein expression for CYP19A1
Considering that T levels in female placentas of the inter-
vention group were significantly increased, we hypothesized
that increased T levels might be due reduced expression of
aromatase CYP19A1 that slows down the conversion of T
to E2 [54]. Although contradictory data were reported from
humans and animals studies on the impact of n-3 LCPUFA
on circulating T levels [55-59], it was hypothesized that n-3
LCPUFAs influence T production in adult pig testis via their
impact on PGE2 synthesis or their regulation of PPAR-
mediated stearidogenesis [55]. Thus, since n-3 LCPUFA
intervention reduces n-6-LCPUFA and their metabolites,
such as PGE2 [6,23,44], changes in T levels may be me-
diated by altered CYP19A1 levels. Therefore, placental
Figure 3 Biological validation of placental genes in ‘Cell cycle’, ‘Wnt signaling’ and ‘LCPUFA regulation’. Expression levels of genes
representing the pathways ‘Cell cycle’ and ‘Wnt signaling’, as well as ‘LCPUFA regulation’ are shown. The data bars for the four analyzed groups
(Con-F, Con-M, N3-F, N3-M) are differently shaded as depicted by the respective boxes between panel A and B. The expression level of female
placentas of the control group (Con-F) was assigned an arbitrary value of 100% and all other analyzed groups (Con-M, N3-F and N3-M) were
depicted relative to Con-F. Data are presented as mean relative gene expression in % + 95% confidence interval. Statistically significant effects of
specific factors were marked as follows. #, offspring sex; *, n-3 LCPUFA treatment; ‡, interactions. #, * or ‡P < 0.05; # #, * * or ‡‡, P < 0.01; # # # or * * *,
P < 0.001. †, two-way ANOVA on ranks. Con-F, female placentas from the control group; Con-M, male placentas from the control group; N3-F, female
placentas from the n-3 LCPUFA intervention group; N3-M, male placentas from the n-3 LCPUFA intervention group. n, number of validated placentas
per group: Con-F, n = 11; Con-M, n = 9; N3-F, n =10; N3-M, n = 11.
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mined by RT-qPCR and Western blot analyses, respectively.
For CYP19A1 mRNA levels, no significant changes related
to effects of sex or n-3 LCPUFA intervention were ob-
served, however, a trend (P# = 0.093) for higher mRNA
levels in male placentas was observed (Figure 4E). For aro-
matase protein, a trend for lower levels in the intervention
than in the control group was found, but this difference was
also not statistically significant (Figure 4F and G).
Correlation of sex steroid hormone levels in placenta and cord
plasma with regulated placental expression of specific genes
Placental testosterone levels did not significantly correlate
with cord plasma T levels (Rs = − 0.031, P = 0.865, n = 33).However, the E2/T ratio showed a positive, moderate
correlation between placental tissue and cord plasma (Rs =
0.424, P = 0.014, n = 33). There were no significant correla-
tions for the genes CDK6, FZD7, HDAC5, PCNA, and
TGFB1 (Table 2). Only mRNA levels for the ‘Wnt signal-
ing’ genes DVL1 and LRP6 showed significantly positive
correlations with placental E2/T ratio in a weak and
moderate manner, respectively.
To explore further the potential that sex steroid hor-
mones are implicated directly in the observed sex-specific
gene regulation via their hormone receptors, we assessed
if the analyzed target genes depict putative hormone-
responsive elements for the estrogen and androgen recep-
tors between the nearest neighboring gene upstream to
Figure 4 Sex steroid levels in placenta and cord plasma, and aromatase gene and protein expression. Testosterone (T) levels and
estradiol-17-beta/testosterone (E2/T) ratio in cord plasma (A,B) and placenta (C,D) are presented as scatter plots with median. (E) RT-qPCR data
for CYP19A1(aromatase) gene expression for the female placentas of the control group (Con-F) are assigned to an arbitrary value of 100% and
values for all other analyzed groups (Con-M, N3-F, and N3-M) were depicted relative to Con-F. Data are presented as mean relative gene expression in
% + the 95% confidence interval. (F) Representive data from Western blot analyses for CYP19A1 (51 kDa) and GAPDH (36 kDa) are shown. GAPDH was
used for normalization. (G) CYP19A1 protein expression data are summarized in a scatter blot with median. Con-F samples are assigned to an arbitrary
value of 100% and all other analyzed groups were depicted relative to Con-F. Statistical significance was calculated by parametric two-way ANOVA for
RT-qPCR data and non-parametric two-way ANOVA on ranks for all other data. Holm-Sidak post-hoc test was used for group comparisons. Statistically
significant effects of specific factors were marked as follows. #, offspring sex; *, n-3 LCPUFA treatment; ‡, interactions. #, * or ‡, P < 0.05; # # or
* * P < 0.01. Trends (P < 0.1 – 0.05) are shown as the actual P value. Con-F and Con-M, female and male offspring in the control group,
respectively; N3-F and N3-M, female and male offspring in the n-3 LCPUFA intervention group, respectively. Number of analyzed placentas per
group: Con-F, n = 11; Con-M, n = 9; N3-F, n = 10, and N3-M, n = 11. Number of analyzed cord plasma samples per group: Con-F, n = 8;
Con-M, n = 7; N3-F, n = 9; N3-M, n = 9.
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ive strand. In our search, only estrogen receptor alpha re-
sponse elements were found, but no androgen receptor
elements. For the genes involved in cell cycle (ANAPC4,
CDK1, CDK6, HDAC5, MAD2L1, PCNA, and TGFB1),
only for the genes CDK6 and MAD2L1 putative estrogen
receptor alpha binding sites were found, whereas for the
other genes no respective responsive elements were de-
tected. The binding site for CDK6 was located in the gene
body, whereas the binding site for MAD2L1 was located
about 200 kBb upstream of the gene body.
Interestingly, with regard to the analyzed genes in the
pathway ‘Wnt signaling’, for nearly all genes, such as DVL1,FZD7, LRP6, and SFRP1, at least one estrogen receptor
alpha response element was annotated within their gene
body. The same was observed for LPL. In addition, for
CYP19A1, three estrogen receptor alpha response elements
were annotated, which were located about 100 and 30 kBp
upstream, and about 70 kBp downstream of the gene body.
Correlation of regulated placental gene expression with
offspring weight and body composition
Correlation analyses were conducted to evaluate whether
placental differential mRNA expression of specific genes
upon intervention might be associated with placental factors,
body weight and length, or body composition measurements
Table 3 Correlation analyses of significantly regulated
mRNA levels of genes with offspring anthropometric
measurements at birth and one year of life, and with
placental weight
LRP6 DVL1 PCNA CDK6 HDAC5 TGFB1
Birth weight
Rs 0.06 −0.02 0.31 0.33 0.06 −0.15
P 0.719 0.918 0.049 0.042 0.717 0.339
N 41 41 41 38 41 41
Birth weight percentiles
Rs 0.17 −0.04 0.49 0.36 0.04 −0.08
P 0.295 0.795 0.002 0.023 0.826 0.607
N 41 41 38 41 41 41
Birth weight-to-length ratio
Rs 0.06 0.01 0.32 0.26 0.04 −0.19
P 0.721 0.931 0.039 0.111 0.825 0.232
N 41 41 41 38 41 41
Birth weight-to-placental weight ratio
Rs −0.12 0.16 0.08 0.26 0.28 0.18
P 0.471 0.325 0.626 0.111 0.079 0.250
N 41 41 41 38 41 41
Placental weight
Rs 0.13 −0.15 0.12 −0.09 −0.23 −0.30
P 0.402 0.366 0.462 0.595 0.151 0.055
N 41 41 41 38 41 41
Body weight at year-1
Rs 0.03 0.49 0.15 0.22 0.48 0.20
P 0.834 0.001 0.350 0.193 0.002 0.210
N 40 40 40 37 40 40
N, number of analyzed individual samples or subjects; P, P-value for the
correlation; Rs, Spearman-rho correlation coefficient. Bold data represent
significant correlations (P < 0.05).
Table 2 Correlation analyses of placental and cord plasma testosterone levels, and placental estradiol-17ß with
validated sex-specific mRNA expression differences of specific genes
CDK6 PCNA HDAC5 LRP6
PL_T PL_E2/T CP_T PL_T PL_E2/T CP_T PL_T PL_E2/T CP_T PL_T PL_E2/T CP_T
Rs −0.06 0.19 0.08 −0.13 −0.01 −0.03 −0.09 0.18 −0.17 −0.28 0.48 0.13
P 0.734 0.254 0.658 0.422 0.969 0.864 0.591 0.268 0.339 0.080 0.002 0.476
N 38 38 31 41 41 33 41 41 33 41 41 33
DVL1 FZD7 TGFB1
PL_T PL_E2/T CP_T PL_T PL_E2/T CP_T PL_T PL_E2/T CP_T
Rs −0.25 0.32 0.01 0.07 0.06 −0.21 −0.14 0.11 −0.15
P 0.115 0.044 0.955 0.688 0.728 0.233 0.395 0.490 0.422
N 41 41 33 41 41 33 41 41 33
CP_T, cord plasma testosterone; N, number of analyzed individual samples or subjects; P, P-value for the correlation; PL_E2/T, placental estradiol-17ß / testosterone
ratio; PL_T, placental testosterone; Rs, Spearman-rho correlation coefficient. Bold data represent significant correlations (P < 0.05).
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correlations are presented in Table 3 and a complete list of
all calculations is shown in Additional file 1: Table S9.
CDK6 and PCNA mRNA levels showed significantly posi-
tive correlations with birth weight and birth weight percen-
tiles. Additionally, PCNA was also significantly positively
correlated with birth weight/birth length ratio in a weak
manner. Both, DVL1 and HDAC5 were significantly posi-
tively correlated with offspring body weight at one year in a
moderate manner (Table 3). No significant correlations
were found for placental weight and body composition (see
Additional file 1: Table S9).
Discussion
The placenta is indispensable for nutrition and develop-
ment of the mammalian fetus and therefore recognized as
a major target for fetal programming [7,8]. Males and
females show sex-specific differences in organ physiology
and prevalence of major diseases, including autoimmune
diseases, diabetes, and asthma [18,19]. The actions of sex
steroid hormones have been implicated in the susceptibility
to these differences between sexes [10,17-19]. However,
investigations of offspring sex-specific gene expression and
responses in the placenta have been widely neglected [9].
The major finding of our study was that placental gene
expression is different between male and female offspring
of the control group, and that maternal dietary n-3
LCPUFA intervention during pregnancy impacts sex-
specifically placental gene expression predominantly in
female placentas. Our transcriptome data sets suggest
that maternal n-3 LCPUFA intervention counterba-
lanced mostly the sexually dimorphic gene expression
pattern observed in the control group, but also induced
the regulation of other genes resulting in sexually dif-
ferential expression de novo. n-3 LCPUFA-responsive
genes were enriched in several pathways, such as for
‘Adipogenesis’, ‘Cell cycle’, and ‘Wnt signaling’, consistent
with the reported importance of the cell cycle and Wnt
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In addition, the mean centroid value analyses of pathway-
specific gene expression and RT-qPCR data also suggest a
counter-regulation of selected genes and pathways upon
n-3 LCPUFA. Overall, this supports our transcriptome
data on significantly differential gene expression, where
upon n-3 LCPUFA intervention in general more genes
were found to be down-regulated than up-regulated in fe-
male placentas. In the context of adipose tissue growth, it
is important to note that the the general direction of gene
expression for the pathway ‘Adipogenesis’ was indicated to
be up-regulated in female placentas from the intervention
group. The evaluation of offspring sex steroid hormone
levels at birth indicated an impact on placental T and E2/T
ratio upon intervention, however without strong associa-
tions to placental sex-dependent gene expression changes
or to the presence of putative hormone-responsive ele-
ments in the vicinity of the respective genes. Regarding off-
spring adiposity risk, significantly moderate associations of
placental mRNA levels for CDK6, DVL1, HDAC5, and
PCNA with offspring birth weight and birth weight percen-
tiles were observed, but not with body composition in the
first year of age.
Sexually dimorphic gene expression in human control
placentas
In the present study, a considerable number of identified
genes with sexually dimorphic expression are located on
autosomes, but as expected, some genes are also located
on sex chromosomes. This is in line with Sood et al. [15]
describing sex-specifically expressed genes in normal hu-
man term placentas. In contrast, in the study of Tsai et al.
[37] nearly all 36 identified genes with sex-specific expres-
sion in human placenta are located on sex chromosomes
(Additional file 1: Table S4 provides genes identified in the
present study common with genes in the data sets of Sood
et al. [15] and Tsai et al. [37]). Apart from our findings on
genes located on autosomes, the expected confirmation of
sex-specific expression of genes from sex-chromosomes,
serving as an internal control, supports the quality and
validity of our DNA microarray experiments [63]. More-
over, our data are consistent with comprehensive gene ex-
pression analyses between murine male and female organs
that demonstrate sexual dimorphism for genes with rather
small fold gene expression differences (1.2 to 2.0), high
tissue-specificity, and gene locations on sex chromosomes
and autosomes [19].
Gene expression in female placentas is more responsive
to maternal n-3 LCPUFA supplementation than in male
placentas
Our finding that it is important to include offspring sex as
factor in the analyses led to the identification of a substan-
tially increased number of n-3 LCPUFA-responsive genes.Surprisingly, only a few of these genes showed common
regulation in both sexes. Since neither sex-dependent nor
sex-independent analyses of the placental transcriptome
with regard to n-3 LCPUFA intervention during preg-
nancy have been published which could be used for the
evaluation of our results, we compared our data to tran-
scriptome data on non-placental tissues or cells [64,65],
which also show considerable number of regulated genes
between n-3 PUFA intervention and control group in
healthy humans. Rudkowska et al. [65] detected among
many n-3 PUFA-responsive genes in peripheral blood
mononuclear cells only 9 genes that were expressed in
common in both adult males and females. Furthermore,
Gabory et al. [66] showed that in placentas from offspring
mice of mothers, fed control and high-fat diet during
pregnancy, only a small portion of genes (11 out of 178)
displayed sexually dimorphic gene expression which was
common for both dietary groups. These data support our
findings despite the tissue and species differences, and the
lower numbers of microarrays used per group in our study
compared to the studies of Rudkowska et al. [65] and
Gabory et al. [66]. In addition, this might also explain why
we observed only a few n-3 LCPUFA-responsive genes
when placental sex was not considered in the analysis.
Our finding that more genes were significantly regulated
in female placenta upon nutritional intervention is in line
with other reports on placenta. For example, more genes
with significantly regulated placental expression were
found in female offspring in response to maternal asthma
in humans [67] and maternal diet in mice [68]. Clifton
et al. [9] hypothesized that ‘the minimal placental gene al-
terations of the male placenta may be a mechanism which
allows the male fetus to continue growing in an adverse
environment’. However, a maternal supplementation of
n-3 LCPUFAs during pregnancy was suggested to have
beneficial rather than adverse effects [6,69-71]. Therefore,
we propose that the hypothesis of Clifton [9] should be
more generalized towards ‘the minimal gene alterations of
the male placenta may be a mechanism that allows the
male fetus to maintain growth relatively independent of en-
vironmental stimuli’. Conversely, the considerable changes
in gene expression of female placentas might allow the fe-
male fetus to adapt more comprehensively to environmen-
tal stimuli. However, the physiological relevance of the
extensive adaptation of female placental gene expression to
their environment remains to be explored.
Placental cell cycle-associated CDK6 and PCNA gene
expression is correlated with offspring birth weight and
birth weight percentiles
In the present study, the biological validation of n-3
LCPUFA-responsive genes, enriched in at least the pathways
‘Cell cycle’ and ‘Wnt signaling’, confirmed the observed sex-
specific effects of the n-3 LCPUFA intervention. Although
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expression with regard to maternal n-3 LCPUFA interven-
tion during pregnancy [72,73], our finding that n-3 LCPUFA
may affect biological processes associated with cell cycle
and its regulation in the placenta is consistent with these
reports. Klingler et al. [72] showed that a nutritional DHA
and 5-methyltetrahy-drofolate supplementation during
pregnancy increased PCNA protein expression exclusively
in trophoblast cells of the human term placenta. For a
human trophoblast cell line, Johansen et al. [73] showed that
DHA, but not EPA, stimulated cell proliferation. Cell proli-
feration has utmost importance for development and
maintenance of the human placenta as shown for the cyto-
trophoblast and syncytiotrophoblast [60,61], and it has to be
tightly controlled by numerous factors [61] including CDK6
and PCNA [50,74]. Although for human placenta increased
proliferation is rather associated with maternal preeclamp-
sia, anemia, or diabetes [60,75,76], these associations do not
apply to our study, where the mothers who donated the an-
alyzed placentas were healthy without complications during
pregnancy [6]. Hypothesizing that changes in the placenta
upon n-3 LCPUFA intervention during pregnancy are
involved in the programming of offspring obesity risk, we
discovered that placental CDK6 and PCNA mRNA levels
were positively correlated with offspring birth weight and
birth weight percentiles. Interestingly, Zadrozna et al. [77]
showed that in intrauterine growth retardation with associ-
ated lower birth weight less placental cells of terminal villi
expressed PCNA accompanied with reduced cytotropho-
blast cell proliferation. In contrast, we found that higher
PCNA gene expression in placental cells correlated with
higher birth weight and birth weight percentiles. Although,
CDK6 and PCNA gene expression were significantly higher
in female placentas of the intervention group, there were no
substantial differences found for offspring birth weight and
body composition in the first year of age between these
groups neither in the INFAT subpopulation nor in the
whole INFAT population after adjustment for sex and gesta-
tional duration [6]. Our data raise the questions whether
the changes in expression of placental genes and pathways
reflect (i) a counteractive response to the proposed growth
reducing impact of n-3 LCPUFA supplementation on
adipose tissue, or (ii) missing strong associations with the
analyzed offspring anthropometric data, since n-3 LCPUFA
per se does not lead to adipose tissue reduction in early
human infancy as proposed by the data of Ailhaud and
co-workers [4,5].
Placenta and cord blood T levels and E2/T ratio show
only a minor contribution to placental sexually dimorphic
gene expression and sex-specific response to the n-3
LCPUFA intervention
Data on the underlying mechanism(s) mediating sexual
dimorphism are scarce in humans and largely based onobservations from mouse or rodent models [17,53]. Sex
steroid hormones are thought to provide the initiation of
sexual differentiation in somatic tissue, but also genes
from the sex chromosomes contribute to differential gene
expression between male and female somatic tissues [17].
As a start to get molecular insights into the molecular
mechanisms mediating the observed sexually dimorphic
gene expression and potential fetal programming effects,
in this study, we analyzed sex steroid hormone levels and
related significant changes to offspring placental gene ex-
pression and body composition.
For placental estrogene and testosterone, our mea-
sured T and E2 levels were in the same range as reported
by other antibody-based approaches [78-80]. Our mea-
sured E2/T ratios in cord plasma were not significantly
different between the control and intervention groups,
and cord T levels were lower in female than male off-
spring. These data are in accordance with a meta-analysis
on sex differences in human cord plasma T levels [81]. Im-
portantly, we discovered lower E2/T ratio in female than
male placentas due to higher T levels in female than male
offspring placenta without differences in E2 levels between
the sexes. Furthermore, we detected that these placental
sex-differences in T levels and E2/T ratio were even en-
hanced upon the intervention. The placenta can act as bar-
rier protecting mutually mother and fetus from an excess
of different factors, including T [82,83]. E2/T ratio is often
used as an indirect marker for the activity of aromatase
(CYP19A1) which is the key enzyme for the conversion of
T to E2 or androstenedione to estrone [54,84,85]. Consider-
ing the data of Sathishkumar et al. [83], that aromatase
mRNA and protein expression were lower in female than
male placentas in normal human pregnancies, suggested re-
duced E2/T ratios due to lower E2 and/or increased T
levels. Therefore, we hypothesized that the increased T
levels in female placentas form the n-3 LCPUFA interven-
tion group might be due to a downregulated expression of
CYP19A1. Our gene and protein expression data however
show a tendatively higher gene expression in male placentas,
and tendatively decreased CYP19A1 protein expression
upon intervention. With regard to the impact of n-3
LCPUFA on circulating T levels in other human and animal
studies on [55-59], it was also suggested that n-3 LCPUFAs
influence T production in adult pig testis via their impact
on PGE2 synthesis or their regulation of PPAR-mediated
stearidogenesis [55]. Whether similar mechanisms are op-
erating in the placenta needs detailed analysis in future
research.
The observed altered placental T levels and E2/T ratio
implied to be involved in the observed sex-specific
gene expression which is in accordance with Clifton [9].
However, our analyses showed that for placental E2/T ratio
or cord plasma T levels in total only two out of 7 genes
with sex-specific regulations were significantly correlated
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minor extent in the direct regulation of these genes. This is
in concordance with Mao et al. [68] showing at least in
mice that different maternal nutrition during pregnancy led
to sexual dimorphism in the placental transcriptome at a
time-point where the contribution of sex hormones seems
unlikely.
Our bioinformatical approach to evaluate the potential
that sex steroid hormones are implicated directly in the
observed sex-specific gene regulation via their hormone
receptors and putative hormone-responsive elements in
the vicinity of identified target genes, surprisingly revealed
only estrogen receptor alpha response elements for some
of the genes, but no androgen receptor elements. Interest-
ingly, with regard to the 'Wnt signaling' genes DVL1,
FZD7, LRP6, and SFRP1 at least one estrogen receptor
alpha response element was annotated. The same was ob-
served for LPL, and for CYP19A1 three estrogen receptor
alpha response elements were annotated.
Altogether, these observations raise several questions re-
garding the underlying mechanisms of sexually dimorphic
gene expression and respective potential involvement of
sex steroid hormones, such as (i) whether changes in E2/
T ratios can modulate estrogen-driven gene regulation, (ii)
if the analyzed placental hormones and their receptors
mediated their action in addition to direct binding to cog-
nate DNA sequences by indirect mechanisms such as re-
cruitment to DNA through other transcription factors
(tethering), or (iii) if affected gene transcription was the
result of signaling cascades by non-genomic mechanisms
of hormone action. Thus, more specific and detailed re-
search is needed to find molecular insights into how sexu-
ally dimorphic gene expression in human somatic tissues,
and in clinical traits such as obesity, artherosclerosis, and
cardiovascular diseases, is regulated, and its underlying
mechanistic relations to endo- and intracrinology.
Conclusions
Altogether, we revealed sexually dimorphic gene expres-
sion in the human term placenta and discovered for the
first time that maternal dietary n-3 LCPUFA intervention
during pregnancy has a more pronounced impact on
female than male placental gene expression, especially in
the biological process of cell cycle. Our data underscore
the importance to perform sex-specific analysis for the
detection of sex-biased differences which will contribute
to a better understanding of embryonic/extraembryonic
development, biomedical research, and fetal and metabolic
programming of offspring health and disease risk. Despite
the absence of impact on birth weight or body compos-
ition upon n-3 LCPUFA intervention, the observed n-3
LCPUFA-responsive changes in placental gene expression
pattern may contribute to programming effects on adipose
tissues which may manifest later in life or on other tissuesand physiological processes that have not been yet ex-
plored. Moreover, it will be interesting to investigate
whether the observed n-3 LCPUFA-responsive gene ex-
pression changes in the placenta mirror gene activities
and underlying epigenetic mechanisms which might also
operate in maternal or other offspring tissues.
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